JAK2V617F activating mutation is associated with the myeloproliferative type of chronic myelomonocytic leukaemia

Journal of Clinical Pathology

Volumn 62, Issue 9, 2009, Pages 798-801

  Pich, Achille ^a   Riera, L ^b   Sismondi, F ^b   Godio, L ^a   Bonino, L Davico ^a   Marmont, F ^c   Di Celle, P Francia ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b Center for Experimental Research and Medical Studies CERMS   (Italy)

^c MOLINETTE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2; JANUS KINASE 2 V617F PROTEIN; UNCLASSIFIED DRUG; DNA; JAK2 PROTEIN, HUMAN;

AGED; ARTICLE; BLOOD; BONE MARROW; BONE MARROW BIOPSY; BONE MARROW CELL; CANCER CLASSIFICATION; CELL HYPERPLASIA; CHRONIC MYELOID LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; ERYTHROPOIESIS; EXON; FIBROSIS; GENE MUTATION; GENETIC ASSOCIATION; HEMOGLOBIN BLOOD LEVEL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MEGAKARYOCYTE; MYELOPROLIFERATIVE DISORDER; NEUTROPHIL COUNT; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SPLENOMEGALY; ADULT; BIOPSY; FEMALE; GENETICS; LEUKOCYTE COUNT; MALE; METHODOLOGY; MIDDLE AGED; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; THROMBOCYTE COUNT;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY; BONE MARROW; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; HUMANS; JANUS KINASE 2; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; LEUKOCYTE COUNT; MALE; MIDDLE AGED; MUTATION; PLATELET COUNT;

EID: 70349100374     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jcp.2009.065904     Document Type: Article

References (17)

1. González-Medina I, Bueno J, Torrequebrada A, et al. Two groups of chronic myelomonocytic leukaemia: myelodysplastic and myeloproliferative. Prognostic implications in a series of a single center. Leuk Res 2002;26:821-824
2. Cortes J. CMML: a biologically distinct myeloproliferative disease. Curr Hematol Rep 2003;2:202-208
3. Onida F, Beran M. Chronic myelomonocytic leukemia: myeloproliferative variant. Curr Hematol Rep 2004;3:218-226
4. Orazi A, Bennett JM, Germing U, et al. Chronic myelomonocytic leukaemia. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th edn. Lyon: IARC Press, 2008:75-79
5. Baxter EJ, Scott LM, Campbell PJ, et al. Cancer Genome Project. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054-1061
6. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7:387-397 (Pubitemid 40544655)
7. James C, Ugo V, Le Couédic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144-1148 (Pubitemid 40663494)
8. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779-1790 (Pubitemid 40570926)
9. Xiao Z, Zhang Y, Li L, et al. The Janus kinase 2 (JAK2) V617F mutation in Chinese patients with chronic myeloproliferative disorders. Haematologica 2008;93:787-788 (Pubitemid 351669324)
10. Levine RL, Loriaux M, Huntly BJ, et al. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood 2005;106:3377-3379 (Pubitemid 41609169)
11. Jelinek J, Oki Y, Gharibyan V, et al. JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood 2005;106:3370-3373
12. Steensma DP, Dewald GW, Lasho TL, et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. Blood 2005;106:1207-1209
13. Thiele J, Kvasnicka HM, Facchetti F, et al. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica 2005;90:1128-1132 (Pubitemid 41323513)
14. Thiele J, Kvasnicka HM, Schmitt-Graeff A, et al. Bone marrow changes in chronic myelogenous leukaemia after long-term treatment with the tyrosine kinase inhibitor STI571: an immunohistochemical study on 75 patients. Histopathology 2005;46:540-550 (Pubitemid 40632311)
15. van Dongen JJ, Macintyre EA, Gabert JA, et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia 1999;13:1901-1928
16. Dixon WJ, Brown MG, Engelman L, et al. BMPD statistical software manual. Berkeley, CA: University of California Press, 1990.
17. Voglová J, Chrobák L, Neuwirtová R, et al. Myelodysplastic and myeloproliferative type of chronic myelomonocytic leukaemia - distinct subgroups or two stages of the same disease? Leuk Res 2001;5:493-499